{"success":true,"data":{"pressRelease":{"id":"119872","rtpr_id":"nACSnSK31a","ticker":"RVV","exchange":"","all_tickers":["RVV"],"title":"Revive Therapeutics Reports Grant of Options","author":"ACCESSWIRE","published_at":"2026-08-14T22:50:27.413Z","article_body":"TORONTO, ON / ACCESS Newswire (https://www.accessnewswire.com/) / August 14,\n2026 / Revive Therapeutics Ltd. (\"Revive\" or the \"Company\")\n(OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the\nresearch and development of therapeutics for biodefence and pandemic\npreparedness, today announced the Board of Directors of Revive has authorized\nthe grant of an aggregate of 15,500,000 incentive stock options to key members\nof our team, including directors, officers, and consultants. The stock options\nhave an exercise price of $0.05 per share for a period of five years. All\nOptions were granted pursuant to the Company's 10% rolling stock option plan\n(the \"Plan\") and are subject to the terms of the Plan, the applicable grant\nagreement and the requirements of the CSE. These stock options are an\nessential component of our strategy to drive performance and incentivize\nexcellence as we advance our corporate objectives.\n\nAbout Revive Therapeutics Ltd.\n\nRevive Therapeutics is a life sciences company focused on the research and\ndevelopment of therapeutics for biodefence and pandemic preparedness. For more\ninformation, visit www.revivethera.com.\n\nFor more information, please contact:\n\nMichael Frank\nChief Executive Officer\nRevive Therapeutics Ltd.\nTel: 1-888-901-0036\nEmail: mfrank@revivethera.com\nWebsite: www.revivethera.com\n\nSOURCE: Revive Therapeutics Ltd.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/revive-therapeutics-reports-grant-of-options-1207669)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSnSK31a","title":"Revive Therapeutics Reports Grant of Options","author":"ACCESSWIRE","ticker":"RVV","created":"2026-08-14T22:50:27.413Z","tickers":["RVV"],"exchange":"","article_body":"TORONTO, ON / ACCESS Newswire (https://www.accessnewswire.com/) / August 14,\n2026 / Revive Therapeutics Ltd. (\"Revive\" or the \"Company\")\n(OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the\nresearch and development of therapeutics for biodefence and pandemic\npreparedness, today announced the Board of Directors of Revive has authorized\nthe grant of an aggregate of 15,500,000 incentive stock options to key members\nof our team, including directors, officers, and consultants. The stock options\nhave an exercise price of $0.05 per share for a period of five years. All\nOptions were granted pursuant to the Company's 10% rolling stock option plan\n(the \"Plan\") and are subject to the terms of the Plan, the applicable grant\nagreement and the requirements of the CSE. These stock options are an\nessential component of our strategy to drive performance and incentivize\nexcellence as we advance our corporate objectives.\n\nAbout Revive Therapeutics Ltd.\n\nRevive Therapeutics is a life sciences company focused on the research and\ndevelopment of therapeutics for biodefence and pandemic preparedness. For more\ninformation, visit www.revivethera.com.\n\nFor more information, please contact:\n\nMichael Frank\nChief Executive Officer\nRevive Therapeutics Ltd.\nTel: 1-888-901-0036\nEmail: mfrank@revivethera.com\nWebsite: www.revivethera.com\n\nSOURCE: Revive Therapeutics Ltd.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/revive-therapeutics-reports-grant-of-options-1207669)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-08-14T22:50:27.47409508Z","server_sent_at_ms":1786747827474},"received_at":"2026-08-14T22:50:27.526Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/revive-therapeutics-reports-grant-of-options-1207669"},"analysis":{"id":"108861","press_release_id":"119872","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Revive Therapeutics granted 15.5 million incentive stock options to key members of its team, including directors, officers, and consultants.\n\nThe options carry an exercise price of $0.05 per share and are valid for a five-year period under the Company's 10% rolling stock option plan.\n\nManagement stated that these grants are essential to its strategy for driving performance and incentivizing excellence as the company advances its corporate objectives.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine compensation grant via stock options."},"keyFigures":{"customDimensions":{"term_years":5,"exercise_price":0.05,"options_granted":15500000}},"quotedText":"These stock options are an essential component of our strategy to drive performance and incentivize excellence as we advance our corporate objectives.","namedEntities":{"people":[{"name":"Michael Frank","role":"Chief Executive Officer"}],"products":[],"companies":[{"name":"Revive Therapeutics Ltd.","ticker":"RVV"}],"dollarAmounts":[{"amount":"$0.05","context":"exercise price per share"}]},"materialImpact":{"score":1,"reasoning":"Routine grant of incentive stock options to directors, officers, and consultants under an existing 10% rolling plan. The event represents standard corporate governance and compensation rather than a material operational or financial shift."},"tickerRelevance":{"others":[],"primary":"RVV"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro_cap","eventGravity":"routine_compensation"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Revive Therapeutics granted 15.5 million incentive stock options to key members of its team, including directors, officers, and consultants.\n\nThe options carry an exercise price of $0.05 per share and are valid for a five-year period under the Company's 10% rolling stock option plan.\n\nManagement stated that these grants are essential to its strategy for driving performance and incentivizing excellence as the company advances its corporate objectives.","key_figures":{"customDimensions":{"term_years":5,"exercise_price":0.05,"options_granted":15500000}},"named_entities":{"people":[{"name":"Michael Frank","role":"Chief Executive Officer"}],"products":[],"companies":[{"name":"Revive Therapeutics Ltd.","ticker":"RVV"}],"dollarAmounts":[{"amount":"$0.05","context":"exercise price per share"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-14T22:54:10.840Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"micro_cap","eventGravity":"routine_compensation"}},"durationMs":null,"modelName":"glm-4.7"}}